Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Illumina, Inc. (ILMN:NASDAQ), powered by AI.
Illumina, Inc. is currently trading at $164.28. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Illumina, Inc. on Alpha Lenz.
Illumina, Inc.'s P/E ratio is 30.0.
“Illumina, Inc. trades at a P/E of 30.0 (premium valuation) with strong ROE of 33.4%.”
Ask for details →Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
“Illumina, Inc. trades at a P/E of 30.0 (premium valuation) with strong ROE of 33.4%.”
Ask for details →Illumina, Inc. (ticker: ILMN) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 8,970 employees. Market cap is $25.5B.
The current price is $164.28 with a P/E ratio of 29.96x and P/B of 9.35x.
ROE is 33.36% and operating margin is 18.81%. Annual revenue is $4.3B.